Developing NIK-blocking small molecules for cancer and autoimmune disease
Overactive NIK signalling can help cancer cells survive, grow and resist treatment. In autoimmune diseases such as lupus and rheumatoid arthritis, NIK can overactivate B cells, contributing to chronic inflammation and progressive tissue damage.
Nikaia Pharmaceuticals is developing small molecules that block NIK, a protein involved in cancer and immune signalling. Its preclinical approach aims to tackle cancer treatment resistance and reduce inflammation in autoimmune disease.
What stands out about Nikaia Pharmaceuticals
Conducted preclinical research on NIK degraders, reporting suppression of tumour growth and activity against treatment resistance.
Co-founded by Thierry Passeron, professor and head of dermatology at Nice University Hospital.
Co-founded by Rachid Benhida, a chemistry research director at CNRS's Institute of Chemistry in Nice.
Co-founded by Thierry Passeron and Rachid Benhida, who previously co-founded NIK-targeting biotech Yukin Therapeutics in 2018.
Tell us about your company and what you're looking to achieve.